Aktie A3CR1N CARSGEN THERAPEUTICS HOLDINGS LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen CARsgen Therapeutics Holdings Limited

Aktien

A3CR1N

KYG1996C1006

2171

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:08:42 28.06.2024 		% 5 Tage % 1. Jan.
4.8 HKD -2.04% Intraday Chart für CARsgen Therapeutics Holdings Limited -13.36% -26.15%
27.06. Großaktionär von CARsgen Therapeutics erhöht seinen Anteil auf 37,78% MT
15.06. CARsgen Therapeutics Holdings Limited präsentiert auf dem EHA 2024 die ersten Ergebnisse einer Studie mit dem GPRC5D-Targeting CAR-T CT071 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
CARsgen Therapeutics' Substantial Shareholder Boosts Stake to 37.78%
CARsgen Therapeutics Holdings Limited Presents First-In-Human Results of GPRC5D Targeting CAR-T CT071 At EHA 2024
Carsgen Therapeutics Holdings Limited Provides Updated Research Results on SATRI-CEL in Nature Medicine And At the 2024 Asco Annual Meeting
CARsgen Therapeutics Holdings Limited commences an Equity Buyback Plan for 57,564,391 shares, representing 10% of its issued share capital, under the authorization approved on May 21, 2024.
CARsgen Submitted Responses to FDA Observations
CARsgen Therapeutics Holdings Limited Announces Abstracts from the Ongoing Studies of zevorcabtagene autoleucel and CT071 to be Presented as an Oral Presentation and a Poster Presentation, Respectively, at the Upcoming EHA 2024
CARsgen Therapeutics Holdings Limited Announces Board and Committee Changes
CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations
Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024
CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023
NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
CARsgen Therapeutics’ New Drug Application for Multiple Myeloma Drug Gets Approval from Chinese Regulator
National Medical Products Administration of China Approves New Drug Application of CARsgen Therapeutics Holdings Limited for Zevorcabtagene Autoleucel
CARsgen Presents Data from Phase 1B Study on Gastric, Gastroesophageal Junction Cancer Drug at US Meet
Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting
CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage a hepatocellular carcinoma at high risk of recurrence after surgical resection
China Grants CARsgen Clinical Trial Clearance for Liver Cancer Treatment; Shares Rise 3%
CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug Clearance from the National Medical Products Administration
CARsgen Therapeutics Holdings Shareholder Plans Stake Boost; Shares Fall 6%
US FDA Puts CARsgen's Three Drug Candidates Under Clinical Hold Following Factory Inspections; Shares Plummet 27%
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3CR1N Aktie
  4. Nachrichten CARsgen Therapeutics Holdings Limited
  5. Andere Sprachen